Acerus Announces Termination Of NATESTO Agreement With Endo

(RTTNews) - Acerus Pharmaceuticals Corp. announced that the agreement with Endo Ventures Bermuda Limited, an affiliate of Endo International plc. (ENDP), relating to the commercialization of NATESTO in the United States and Mexico will be terminated, effective June 30, 2016.

Under the terms of the agreement with Acerus, Endo will continue to sell and distribute NATESTO™ in the U.S. until the effective date of termination.

"While we are disappointed with Endo's previously announced strategic business decision to realign their U.S. branded resources from urology retail to their pain franchise, we are fully committed to the continued success of NATESTO in the U.S.," said Tom Rossi, President and Chief Executive Officer of Acerus. "Our immediate focus is on finding a new NATESTO™ partner in the U.S., the largest market for testosterone replacement therapy."